Evidence map›Paper›PMID 12883533›Full record

ArticleGene therapy2003

Synthesis of adenoviral targeting molecules by intein-mediated protein ligation.

O Nyanguile, C Dancik, J Blakemore, K Mulgrew, M Kaleko, S C Stevenson

Abstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents.Proceedings of the National Academy of Sciences of the United States of America · 2006
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

O NyanguileGenetic Therapy, Inc., A Novartis Company, Gaithersburg, MD 20878, USA.
C Dancik
J Blakemore
K Mulgrew
M Kaleko
S C Stevenson
Novartis (Switzerland) · CHResearch Institute for Genetic and Human Therapy · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adenoviral vectors infect cells through the binding of capsid proteins to cell-surface receptors. The ubiquitous expression of adenoviral receptors in human tissues represents an obstacle toward the development of systemically deliverable vectors for cancer therapy, since effective therapy may require delivery to specific sites. For these reasons, major efforts are directed toward the elimination of the native tropism combined with identification of ligands that bind to tumor-specific cell-surface proteins. Highthroughput technologies have identified potential targeting ligands, which need to be evaluated for their ability to retarget adenovirus to alternative receptors. Here, we present a strategy that permits the routine analysis of adenoviral targeting ligands. We use intein-mediated protein ligation as a means to produce functional biological molecules, that is, adenoviral targeting molecules that function as adapters between cellular receptors and the adenovirus fiber protein. We demonstrate the versatility of the present system by conjugating targeting ligands that differ in size and nature including an apolipoprotein E synthetic peptide, the basic fibroblast growth factor and folic acid. The resulting adenoviral targeting molecules mediate adenoviral gene delivery in cells that express the corresponding receptor.

Indexed as

AdenoviridaeApolipoproteins EFibroblast Growth Factor 2Folic AcidGenetic EngineeringGenetic TherapyGenetic VectorsHumansLigandsNeoplasmsProtein BindingReceptors, Cell SurfaceTumor Cells, CulturedApolipoproteins EFibroblast Growth Factor 2Folic AcidLigandsReceptors, Cell Surface

Identifiers

PMID12883533
OpenAlexW2105598627

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.